Zofingen - Life sciences company Siegfried from the Swiss canton of Aargau has received approval from the relevant competition authorities to acquire production sites in the United States and Australia. These locations will be used to develop small-molecule active ingredients. The transaction is scheduled to close on 1 May 2026.
(CONNECT) Siegfried AG, a contract development and manufacturing company for the pharmaceutical industry, has obtained clearance to acquire three production sites for small-molecule active pharmaceutical ingredients. The Zofingen-based life sciences company is purchasing Noramco, a site for commercial active ingredient production in Wilmington, Delaware as well as Purisys, a development and production facility for clinical active ingredients in Athens, Georgia and Extractas Bioscience, a manufacturer of purified products based in Westbury in Tasmania, Australia. The closing of the transaction is scheduled for 1 May 2026. These acquisitions strengthen Siegfried’s ability to support customers throughout the entire pharmaceutical production cycle, reads a statement from the company.
As part of the acquisition, Siegfried is also updating its financial outlook for the fiscal year 2026. The company expects a net sales contribution of approximately 100 million US dollars and an EBITDA margin (earnings before interest, taxes, depreciation, and amortization) at or above the current group level.
For the Drug Substances segment, expected net sales growth is now in the high-single-digit percentage range in local currencies (previously low-single-digit percentage range). The expected growth of net sales remains unchanged in the high-single-digit percentage range for the Drug Products cluster. As a result, Siegfried is raising its forecast for net sales growth across the group from the low- to the high-single-digit percentage range in local currencies.
“The additional US manufacturing capacity and complementary capabilities strengthen our position in small-molecule drug substances and support our ambition to deliver sustainable, profitable growth,” Marcel Imwinkelried, CEO of Siegfried, is quoted as saying. “We look forward to welcoming our new colleagues to Siegfried and to working together to further strengthen our global network and realize its full potential.” ce/ja
